The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Advances and challenges in targeting FGFR signalling in cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Patterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
COSMIC: exploring the world's knowledge of somatic mutations in human cancer
Forbes, S. A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., Ding, M., Bamford, S., Cole, C., Ward, S., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1075 · Cited by 2,283
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
Hunter, D. J., Kraft, P., Jacobs, K. B., Cox, D. G., Yeager, M., Hankinson, S. E., Wacholder, S., Wang, Z., Welch, R., Hutchinson, A., et al. (2007) · Nature Genetics · doi:10.1038/ng2075 · Cited by 1,481
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Peifer, M., Fernández-Cuesta, L., Sos, M. L., George, J., Seidel, D., Kasper, L. H., Plenker, D., Leenders, F., Sun, R., Zander, T., et al. (2012) · Nature Genetics · doi:10.1038/ng.2396 · Cited by 1,397
Shihab, H. A., Gough, J., Cooper, D. N., Stenson, P. D., Barker, G. L. A., Edwards, K. J., Day, I. N. M., & Gaunt, T. R. (2013) · Human Mutation · doi:10.1002/humu.22225 · Cited by 1,341
O'Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.028 · Cited by 1,259
Structural and Functional Diversity in the FGf Receptor Multigene Family
(1992) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60821-0 · Cited by 1,250
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
Garcia-Murillas, I., Schiavon, G., Weigelt, B., Ng, C., Hrebien, S., Cutts, R. J., Cheang, M., Osin, P., Nerurkar, A., Kozarewa, I., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab0021 · Cited by 1,150
Self-citationA Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306494 · Cited by 1,142
Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
Yu, M., Bardia, A., Aceto, N., Bersani, F., Madden, M. W., Donaldson, M. C., Desai, R., Zhu, H., Comaills, V., Zheng, Z., et al. (2014) · Science · doi:10.1126/science.1253533 · Cited by 913
Kimelman, D., & Kirschner, M. (1987) · Cell · doi:10.1016/0092-8674(87)90110-3 · Cited by 874
Weiss, J., Sos, M. L., Seidel, D., Peifer, M., Zander, T., Heuckmann, J. M., Ullrich, R. T., Menon, R., Maier, S., Soltermann, A., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001451 · Cited by 821
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Helsten, T., Elkin, S., Arthur, E., Tomson, B. N., Carter, J., & Kurzrock, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3212 · Cited by 808
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Singh, D., Chan, J. M., Zoppoli, P., Niola, F., Sullivan, R., Castano, A., Liu, E. M., Reichel, J., Porrati, P., Pellegatta, S., et al. (2012) · Science · doi:10.1126/science.1220834 · Cited by 789
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Wu, Y.-M., Su, F., Kalyana-Sundaram, S., Khazanov, N., Ateeq, B., Cao, X., Lonigro, R. J., Vats, P., Wang, R., Lin, S.-F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0050 · Cited by 744
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M. A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3746 · Cited by 732
Self-citationFrequent activating mutations of FGFR3 in human bladder and cervix carcinomas
Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J. P., & Radvanyi, F. (1999) · Nature Genetics · doi:10.1038/12615 · Cited by 713
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Crystal, A. S., Shaw, A. T., Sequist, L. V., Friboulet, L., Niederst, M. J., Lockerman, E. L., Frias, R. L., Gainor, J. F., Amzallag, A., Greninger, P., et al. (2014) · Science · doi:10.1126/science.1254721 · Cited by 708
Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease
Itoh, N., & Ornitz, D. M. (2011) · Journal of Biochemistry · doi:10.1093/jb/mvq121 · Cited by 705
Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2
Ortega, S., Ittmann, M., Tsang, S. H., Ehrlich, M., & Basilico, C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.10.5672 · Cited by 593
Arai, Y., Totoki, Y., Hosoda, F., Shirota, T., Hama, N., Nakamura, H., Ojima, H., Furuta, K., Shimada, K., Okusaka, T., et al. (2014) · Hepatology · doi:10.1002/hep.26890 · Cited by 553
Goyal, L., Saha, S. K., Liu, L. Y., Siravegna, G., Leshchiner, I., Ahronian, L. G., Lennerz, J. K., Vu, P., Deshpande, V., Kambadakone, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1000 · Cited by 552
Gavine, P. R., Mooney, L., Kilgour, E., Thomas, A. P., Al-Kadhimi, K., Beck, S., Rooney, C., Coleman, T., Baker, D., Mellor, M. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3034 · Cited by 501
Kopetz, S., Hoff, P. M., Morris, J. S., Wolff, R. A., Eng, C., Glover, K. Y., Adinin, R., Overman, M. J., Valero, V., Wen, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8252 · Cited by 485
Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain
Mohammadi, M. (1998) · The EMBO Journal · doi:10.1093/emboj/17.20.5896 · Cited by 482
Guagnano, V., Furet, P., Spanka, C., Bordas, V., Le Douget, M., Stamm, C., Brueggen, J., Jensen, M. R., Schnell, C., Schmid, H., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2006222 · Cited by 477
Nguyen, M., Watanabe, H., Budson, A. E., Richie, J. P., Hayes, D. F., & Folkman, J. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.5.356 · Cited by 464
Chaffer, C. L., Brennan, J. P., Slavin, J. L., Blick, T., Thompson, E. W., & Williams, E. D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2044 · Cited by 455
Pietras, K., Pahler, J., Bergers, G., & Hanahan, D. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050019 · Cited by 453
Sawey, E. T., Chanrion, M., Cai, C., Wu, G., Zhang, J., Zender, L., Zhao, A., Busuttil, R. W., Yee, H., Stein, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.040 · Cited by 436
Nogova, L., Sequist, L. V., Perez Garcia, J. M., Andre, F., Delord, J.-P., Hidalgo, M., Schellens, J. H. M., Cassier, P. A., Camidge, D. R., Schuler, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.2048 · Cited by 432
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Degirolamo, C., Sabbà, C., & Moschetta, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.9 · Cited by 424
Turner, N., Lambros, M. B., Horlings, H. M., Pearson, A., Sharpe, R., Natrajan, R., Geyer, F. C., van Kouwenhove, M., Kreike, B., Mackay, A., et al. (2010) · Oncogene · doi:10.1038/onc.2009.489 · Cited by 416
Self-citationDieci, M. V., Arnedos, M., Andre, F., & Soria, J. C. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0362 · Cited by 406
A combinatorial strategy for treating KRAS-mutant lung cancer
Manchado, E., Weissmueller, S., Morris, J. P., Chen, C.-C., Wullenkord, R., Lujambio, A., de Stanchina, E., Poirier, J. T., Gainor, J. F., Corcoran, R. B., et al. (2016) · Nature · doi:10.1038/nature18600 · Cited by 403
Yan, G., Fukabori, Y., McBride, G., Nikolaropolous, S., & McKeehan, W. L. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.8.4513 · Cited by 403
Spatial and temporal patterns of ERK signaling during mouse embryogenesis
Corson, L. B., Yamanaka, Y., Lai, K.-M. V., & Rossant, J. (2003) · Development · doi:10.1242/dev.00669 · Cited by 390
Oncogenic FGFR3 gene fusions in bladder cancer
Williams, S. V., Hurst, C. D., & Knowles, M. A. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds486 · Cited by 390
Tabernero, J., Bahleda, R., Dienstmann, R., Infante, J. R., Mita, A., Italiano, A., Calvo, E., Moreno, V., Adamo, B., Gazzah, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.7341 · Cited by 388
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
Dienstmann, R., Rodon, J., Prat, A., Perez-Garcia, J., Adamo, B., Felip, E., Cortes, J., Iafrate, A. J., Nuciforo, P., & Tabernero, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt419 · Cited by 365
Tomlinson, D., Baldo, O., Harnden, P., & Knowles, M. (2007) · The Journal of Pathology · doi:10.1002/path.2207 · Cited by 363
A Mouse Model of Hepatocellular Carcinoma
Nicholes, K., Guillet, S., Tomlinson, E., Hillan, K., Wright, B., Frantz, G. D., Pham, T. A., Dillard-Telm, L., Tsai, S. P., Stephan, J.-P., et al. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61177-7 · Cited by 359
FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Guagnano, V., Kauffmann, A., Wöhrle, S., Stamm, C., Ito, M., Barys, L., Pornon, A., Yao, Y., Li, F., Zhang, Y., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0210 · Cited by 347
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Dutt, A., Salvesen, H. B., Chen, T.-H., Ramos, A. H., Onofrio, R. C., Hatton, C., Nicoletti, R., Winckler, W., Grewal, R., Hanna, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803379105 · Cited by 345
Subtyping of triple‐negative breast cancer: Implications for therapy
Abramson, V. G., Lehmann, B. D., Ballinger, T. J., & Pietenpol, J. A. (2015) · Cancer · doi:10.1002/cncr.28914 · Cited by 333
VI, J. G. T., Cheuk, A. T., Tsang, P. S., Chung, J.-Y., Song, Y. K., Desai, K., Yu, Y., Chen, Q.-R., Shah, K., Youngblood, V., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39703 · Cited by 321
Hagel, M., Miduturu, C., Sheets, M., Rubin, N., Weng, W., Stransky, N., Bifulco, N., Kim, J. L., Hodous, B., Brooijmans, N., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1029 · Cited by 313
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.
Bange, J., Prechtl, D., Cheburkin, Y. V., Specht, K., Harbeck, N., Schmitt, M., Knyazeva, T., Müller, S., Gärtner, S., Sures, I., et al. (2002) · PubMed · Cited by 312
Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
André, F., Bachelot, T., Campone, M., Dalenc, F., Perez-Garcia, J. M., Hurvitz, S. A., Turner, N., Rugo, H., Smith, J. W., Deudon, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0190 · Cited by 311
Self-citationSia, D., Losic, B., Moeini, A., Cabellos, L., Hao, K., Revill, K., Bonal, D., Miltiadous, O., Zhang, Z., Hoshida, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms7087 · Cited by 311
Acevedo, V. D., Gangula, R. D., Freeman, K. W., Li, R., Zhang, Y., Wang, F., Ayala, G. E., Peterson, L. E., Ittmann, M., & Spencer, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.11.004 · Cited by 308
A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine Kinases
Chen, H., Ma, J., Li, W., Eliseenkova, A. V., Xu, C., Neubert, T. A., Miller, W. T., & Mohammadi, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.028 · Cited by 291
Trudel, S., Li, Z. H., Wei, E., Wiesmann, M., Chang, H., Chen, C., Reece, D., Heise, C., & Stewart, A. K. (2005) · Blood · doi:10.1182/blood-2004-10-3913 · Cited by 289
Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling
Fillmore, C. M., Gupta, P. B., Rudnick, J. A., Caballero, S., Keller, P. J., Lander, E. S., & Kuperwasser, C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007863107 · Cited by 283
Allele-Specific Up-Regulation of FGFR2 Increases Susceptibility to Breast Cancer
Meyer, K. B., Maia, A.-T., O'Reilly, M., Teschendorff, A. E., Chin, S.-F., Caldas, C., & Ponder, B. A. J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060108 · Cited by 280
Hughes, S. E. (1997) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215549704500710 · Cited by 280
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
Hart, K. C., Robertson, S. C., Kanemitsu, M. Y., Meyer, A. N., Tynan, J. A., & Donoghue, D. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203650 · Cited by 276
Pearson, A., Smyth, E., Babina, I. S., Herrera-Abreu, M. T., Tarazona, N., Peckitt, C., Kilgour, E., Smith, N. R., Geh, C., Rooney, C., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1246 · Cited by 276
Self-citationIdentification of a new fibroblast growth factor receptor, FGFR5
Sleeman, M., Fraser, J., McDonald, M., Yuan, S., White, D., Grandison, P., Kumble, K., Watson, J. D., & Murison, J. G. (2001) · Gene · doi:10.1016/s0378-1119(01)00518-2 · Cited by 271
Cyclin D1, EMS1 and 11q13 Amplification in Breast Cancer
Ormandy, C. J., Musgrove, E. A., Hui, R., Daly, R. J., & Sutherland, R. L. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1023033708204 · Cited by 270
FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas
Reis-Filho, J. S., Simpson, P. T., Turner, N. C., Lambros, M. B., Jones, C., Mackay, A., Grigoriadis, A., Sarrio, D., Savage, K., Dexter, T., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1164 · Cited by 270
Self-citationRegulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins
Gotoh, N. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00840.x · Cited by 268
Schuuring, E. (1995) · Gene · doi:10.1016/0378-1119(94)00562-7 · Cited by 268
Motzer, R. J., Porta, C., Vogelzang, N. J., Sternberg, C. N., Szczylik, C., Zolnierek, J., Kollmannsberger, C., Rha, S. Y., Bjarnason, G. A., Melichar, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70030-0 · Cited by 262
Ware, K. E., Hinz, T. K., Kleczko, E., Singleton, K. R., Marek, L. A., Helfrich, B. A., Cummings, C. T., Graham, D. K., Astling, D., Tan, A.-C., et al. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.4 · Cited by 249
Courjal, F., Cuny, M., Simony-Lafontaine, J., Louason, G., Speiser, P., Zeillinger, R., Rodríguez, C., & Theillet, C. G. (1997) · PubMed · Cited by 238
Fibroblast growth factors are required for efficient tumor angiogenesis.
Compagni, A., Wilgenbus, P., Impagnatiello, M.-A., Cotten, M. L., & Christofori, G. (2000) · PubMed · Cited by 227
Shirakihara, T., Horiguchi, K., Miyazawa, K., Ehata, S., Shibata, T., Morita, I., Miyazono, K., & Saitoh, M. (2011) · The EMBO Journal · doi:10.1038/emboj.2010.351 · Cited by 227
Genetic insights into the mechanisms of Fgf signaling
Brewer, J. R., Mazot, P., & Soriano, P. (2016) · Genes & Development · doi:10.1101/gad.277137.115 · Cited by 227
Marek, L., Ware, K. E., Fritzsche, A., Hercule, P., Helton, W. R., Smith, J. E., McDermott, L. A., Coldren, C. D., Nemenoff, R. A., Merrick, D. T., et al. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.049544 · Cited by 222
Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models
French, D. M., Lin, B. C., Wang, M., Adams, C., Shek, T., Hötzel, K., Bolon, B., Ferrando, R., Blackmore, C., Schroeder, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036713 · Cited by 216
Terai, H., Soejima, K., Yasuda, H., Nakayama, S., Hamamoto, J., Arai, D., Ishioka, K., Ohgino, K., Ikemura, S., Sato, T., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0652 · Cited by 206
Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome
Ibrahimi, O. A., Eliseenkova, A. V., Plotnikov, A. N., Yu, K., Ornitz, D. M., & Mohammadi, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121183798 · Cited by 205
FGFs, their receptors, and human limb malformations: Clinical and molecular correlations
Wilkie, A. O. M., Patey, S. J., Kan, S., van den Ouweland, A. M. W., & Hamel, B. C. J. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10775 · Cited by 201
Yadav, V., Zhang, X., Liu, J., Estrem, S., Li, S., Gong, X.-Q., Buchanan, S., Henry, J. R., Starling, J. J., & Peng, S.-B. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.377218 · Cited by 200
Monospecific antibodies implicate basic fibroblast growth factor in normal wound repair.
Broadley, K. N., Aquino, A. M., Woodward, S. C., Buckley, A., Sato, Y., Rifkin, D. B., & Davidson, J. M. (1989) · PubMed · Cited by 198
Zhao, G., Li, W.-Y., Chen, D., Henry, J. R., Li, H.-Y., Chen, Z., Zia-Ebrahimi, M., Bloem, L., Zhai, Y., Huss, K., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0306 · Cited by 189
FGFR2 gene amplification and clinicopathological features in gastric cancer
Matsumoto, K., Arao, T., Hamaguchi, T., Shimada, Y., Kato, K., Oda, I., Taniguchi, H., Koizumi, F., Yanagihara, K., Sasaki, H., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.603 · Cited by 188
Pepper, M. S., Mandriota, S. J., Jeltsch, M., Kumar, V., & Alitalo, K. (1998) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199812)177:3<439::aid-jcp7>3.0.co;2-2 · Cited by 186
Wu, A.-L., Coulter, S., Liddle, C., Wong, A., Eastham-Anderson, J., French, D. M., Peterson, A. S., & Sonoda, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017868 · Cited by 185
Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19
Zhou, M., Wang, X., Phung, V., Lindhout, D. A., Mondal, K., Hsu, J.-Y., Yang, H., Humphrey, M., Ding, X., Arora, T., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0208 · Cited by 183
FRS2α attenuates FGF receptor signaling by Grb2- mediated recruitment of the ubiquitin ligase Cbl
Wong, A., Lamothe, B., Lee, A., Schlessinger, J., & Lax, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052138899 · Cited by 177
Tan, L., Wang, J., Tanizaki, J., Huang, Z., Aref, A. R., Rusan, M., Zhu, S.-J., Zhang, Y., Ercan, D., Liao, R. G., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403438111 · Cited by 174
Soria, J.-C., DeBraud, F., Bahleda, R., Adamo, B., Andre, F., Dientsmann, R., Delmonte, A., Cereda, R., Isaacson, J., Litten, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu390 · Cited by 173
Sharpe, R., Pearson, A., Herrera-Abreu, M. T., Johnson, D., Mackay, A., Welti, J. C., Natrajan, R., Reynolds, A. R., Reis-Filho, J. S., Ashworth, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2727 · Cited by 167
Self-citationInhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma
Liao, R. G., Jung, J., Tchaicha, J., Wilkerson, M. D., Sivachenko, A., Beauchamp, E. M., Liu, Q., Pugh, T. J., Pedamallu, C. S., Hayes, D. N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3950 · Cited by 167
Ibrahimi, O. A., Zhang, F., Eliseenkova, A. V., Itoh, N., Linhardt, R. J., & Mohammadi, M. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh235 · Cited by 163
Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b
Bernard‐Pierrot, I., Brams, A., Dunois-Lardé, C., Caillault, A., de Medina, S. G. D., Cappellen, D., Graff, G., Thiery, J. P., Chopin, D. K., Ricol, D., et al. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi290 · Cited by 157
Wynes, M. W., Hinz, T. K., Gao, D., Martini, M., Marek, L. A., Ware, K. E., Edwards, M. G., Böhm, D., Perner, S., Helfrich, B. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3060 · Cited by 156
Allen, E., Walters, I. B., & Hanahan, D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2847 · Cited by 153
Blencke, S., Zech, B., Engkvist, O., Greff, Z., Őrfi, L., Horváth, Z., Kéri, G., Ullrich, A., & Daub, H. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.02.029 · Cited by 152
Ware, K. E., Marshall, M. E., Heasley, L. R., Marek, L. A., Hinz, T. K., Hercule, P., Helfrich, B. A., Doebele, R. C., & Heasley, L. E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014117 · Cited by 148
Bello, E., Colella, G., Scarlato, V., Oliva, P., Berndt, A., Valbusa, G., Serra, S. C., D’Incalci, M., Cavalletti, E., Giavazzi, R., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2700 · Cited by 148
Chell, V., Balmanno, K., Little, A. S., Wilson, M. I., Andrews, S., Blockley, L., Hampson, M., Gavine, P. R., & Cook, S. J. (2012) · Oncogene · doi:10.1038/onc.2012.319 · Cited by 146
Inducible dimerization of FGFR1
Welm, B. E., Freeman, K. W., Chen, M., Contreras, A., Spencer, D. M., & Rosen, J. M. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200107119 · Cited by 145
Xian, W., Schwertfeger, K. L., Vargo-Gogola, T. C., & Rosen, J. M. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200505098 · Cited by 144
Byron, S. A., Chen, H., Wortmann, A., Loch, D. C., Gartside, M. G., Dehkhoda, F., Blais, S. P., Neubert, T. A., Mohammadi, M., & Pollock, P. M. (2013) · Neoplasia · doi:10.1593/neo.121106 · Cited by 141
Herrera-Abreu, M. T., Pearson, A., Campbell, J., Shnyder, S. D., Knowles, M. A., Ashworth, A., & Turner, N. C. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0569 · Cited by 132
Self-citationFong, C. W., Leong, H. F., Wong, E. S. M., Lim, J., Yusoff, P., & Guy, G. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301317200 · Cited by 129
Angevin, E., Lopez-Martin, J. A., Lin, C., Gschwend, J. E., Harzstark, A. L., Castellano, D., Soria, J., Sen, P., Chang, J. E., Shi, M. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2885 · Cited by 129
Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy
Ronca, R., Giacomini, A., Salle, E. D., Coltrini, D., Pagano, K., Ragona, L., Matarazzo, S., Rezzola, S., Maiolo, D., Torella, R., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.002 · Cited by 125
Nakanishi, Y., Akiyama, N., Tsukaguchi, T., Fujii, T., Sakata, K., Sase, H., Isobe, T., Morikami, K., Shindoh, H., Mio, T., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0248 · Cited by 121
Harding, T. C., Long, L., Palencia, S., Zhang, H., Sadra, A., Hestir, K., Patil, N. S., Levin, A., Hsu, A. W., Charych, D. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005414 · Cited by 120
Azuma, K., Kawahara, A., Sonoda, K., Nakashima, K., Tashiro, K., Watari, K., Izumi, H., Kage, M., Kuwano, M., Ono, M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1866 · Cited by 108
Amplification of FRS2 and Activation of FGFR/FRS2 Signaling Pathway in High-Grade Liposarcoma
Zhang, K., Chu, K., Wu, X., Gao, H., Wang, J., Yuan, Y., Loera, S., Ho, K., Wang, Y., Chow, W. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2086 · Cited by 104
Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines
Campbell, J., Ryan, C. J., Brough, R., Bajrami, I., Pemberton, H. N., Chong, I. Y.-S., Costa-Cabral, S., Frankum, J. R., Gulati, A., Holme, H., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.023 · Cited by 104
Javidi‐Sharifi, N., Traer, E. A., Martinez, J., Gupta, A., Taguchi, T., Dunlap, J. B., Heinrich, M. C., Corless, C. L., Rubin, B. P., Druker, B. J., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0573 · Cited by 99
Sun, H. D., Malabunga, M., Tonra, J. R., DiRenzo, R., Carrick, F. E., Zheng, H., Berthoud, H., McGuinness, O. P., Shen, J., Böhlen, P., et al. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00089.2006 · Cited by 97
Malchers, F., Dietlein, F., Schöttle, J., Lu, X. L., Nogová, L., Albus, K., Fernandez‐Cuesta, L., Heuckmann, J. M., Gautschi, O. P., Diebold, J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0323 · Cited by 96
Wan, X., Corn, P. G., Yang, J., Palanisamy, N., Starbuck, M. W., Efstathiou, E., Tapia, E. M. L. N., Zurita, A. J., Aparicio, A. M., Ravoori, M. K., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009332 · Cited by 96
Okamoto, I., Kaneda, H., Satoh, T., Okamoto, W., Miyazaki, M., Morinaga, R., Ueda, S., Terashima, M., Tsuya, A., Sarashina, A., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0379 · Cited by 94
Tolcher, A. W., Papadopoulos, K. P., Patnaik, A., Wilson, K. M. O., Thayer, S., Zanghi, J. A., Gemo, A. T., Kavanaugh, W. M., Keer, H. N., & LoRusso, P. M. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv591 · Cited by 94
FGF23 promotes prostate cancer progression
Feng, S., Wang, J., Zhang, Y., Creighton, C. J., & Ittmann, M. (2015) · Oncotarget · doi:10.18632/oncotarget.4174 · Cited by 92
Konecny, G. E., Finkler, N. J., García, A. A., Lorusso, D., Lee, P. S., Rocconi, R. P., Fong, P. C. C., Squires, M. S., Mishra, K., Upalawanna, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70159-2 · Cited by 91
Ronca, R., Giacomini, A., Rusnati, M., & Presta, M. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1062475 · Cited by 91
Karlsson, E. A., Waltersson, M. A., Bostner, J., Pérez‐Tenorio, G., Olsson, B., Hallbeck, A., & Stål, O. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20900 · Cited by 84
Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer
Čihorić, N., Savić, S., Schneider, S. S., Ackermann, I., Bichsel-Naef, M., Schmid, R. A., Lardinois, D., Gugger, M., Bubendorf, L., Zlobec, I., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.229 · Cited by 82
Endocrine Fibroblast Growth Factor FGF19 Promotes Prostate Cancer Progression
Feng, S., Dakhova, O., Creighton, C. J., & Ittmann, M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4108 · Cited by 80
Dysregulated FGF signalling in neoplastic disorders
Tanner, Y., & Grose, R. P. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.10.012 · Cited by 79
Roles of intracellular fibroblast growth factors in neural development and functions
Zhang, X., Bao, L., Liu, Y., Wu, Q., & Li, S. (2012) · Science China Life Sciences · doi:10.1007/s11427-012-4412-x · Cited by 76
Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation.
Rosty, C., Aubriot‐Lorton, M., Cappellen, D., Bourdin, J., Cartier, I., Thiery, J. P., Sastre‐Garau, X., & Radvanyi, F. (2005) · Molecular Cancer · doi:10.1186/1476-4598-4-15 · Cited by 76
Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site
Ulaganathan, V. K., Sperl, B., Rapp, U. R., & Ullrich, A. (2015) · Nature · doi:10.1038/nature16449 · Cited by 75
Wang, J., Mikse, O. R., Liao, R. G., Li, Y. Y., Tan, L., Janne, P. A., Gray, N. S., Wong, K., & Hammerman, P. S. (2014) · Oncogene · doi:10.1038/onc.2014.161 · Cited by 72
Chen, J., Chen, G., Yan, Z., Guo, Y., Yu, M., Feng, L., Jiang, Z., Guo, W., & Tian, W. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24610 · Cited by 68
Transforming acidic coiled-coil proteins (TACCs) in human cancer
Ha, G., Kim, J., & Breuer, E.-K. Y. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.04.022 · Cited by 68
Ishiwata, T., Matsuda, Y., Yamamoto, T., Uchida, E., Korc, M., & Naito, Z. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.01.020 · Cited by 67
Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?
André, F., Delaloge, S., & Soria, J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6877 · Cited by 66
Amary, F. M., Ye, H., Berisha, F., Khatri, B., Forbes, G., Lehovsky, K., Frezza, A. M., Behjati, S., Tarpey, P. S., Pillay, N., et al. (2014) · Cancer Medicine · doi:10.1002/cam4.268 · Cited by 63
Singleton, K. R., Hinz, T. K., Kleczko, E. K., Marek, L. A., Kwak, J., Harp, T., Kim, J., Tan, A. C., & Heasley, L. E. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0509 · Cited by 63
Bang, Y., Cutsem, E. V., Mansoor, W., Petty, R., Chao, Y., Cunningham, D., Ferry, D. R., Landers, D., Stockman, P. K., Smith, N. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.4014 · Cited by 59
Gozgit, J. M., Squillace, R. M., Wongchenko, M. J., Miller, D., Wardwell, S., Mohemmad, Q. K., Narasimhan, N. I., Wang, F., Clackson, T., & Rivera, V. M. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2131-z · Cited by 57
Hood, F. E., & Royle, S. (2011) · BioArchitecture · doi:10.4161/bioa.1.3.16518 · Cited by 55
Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor
Frullanti, E., Berking, C., Harbeck, N., Jézéquel, P., Haugen, A., Mawrin, C., Parise, O., Sasaki, H., Tsuchiya, N., & Dragani, T. A. (2011) · European Journal of Cancer Prevention · doi:10.1097/cej.0b013e3283457274 · Cited by 55
HPV16 E5 expression induces switching from FGFR2b to FGFR2c and epithelial-mesenchymal transition
Ranieri, D., Belleudi, F., Magenta, A., & Torrisi, M. R. (2015) · International Journal of Cancer · doi:10.1002/ijc.29373 · Cited by 54
Zhang, X., Mu, X. L., Huang, O., Xie, Z., Jiang, M., Geng, M., & Shen, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072053 · Cited by 54
Competition between Grb2 and Plcγ1 for FGFR2 regulates basal phospholipase activity and invasion
Timsah, Z., Ahmed, Z., Lin, C., Melo, F. A., Stagg, L., Leonard, P. G., Jeyabal, P., Berrout, J., O’Neil, R. G., Bogdanov, M. V., et al. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2752 · Cited by 51
Reynisdóttir, I., Arason, A., Einarsdottir, B. O., Gunnarsson, H., Staaf, J., Vallon‐Christersson, J., Jönsson, G. B., Ringnér, M., Agnarsson, B. A., Ólafsdóttir, K., et al. (2013) · Cancer Medicine · doi:10.1002/cam4.88 · Cited by 47
Metabolic roles of endocrine fibroblast growth factors
Fernandes-Freitas, I., & Owen, B. M. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.09.014 · Cited by 46
FGF19 promotes progression of prostate cancer
Nagamatsu, H., Teishima, J., Goto, K., Shikuma, H., Kitano, H., Shoji, K., Inoue, S., & Matsubara, A. (2015) · The Prostate · doi:10.1002/pros.22994 · Cited by 46
Amplification of Chromosome 8 Genes in Lung Cancer
Baykara, O., Bakır, B., Buyru, N., Kaynak, K., & Dalay, N. (2015) · Journal of Cancer · doi:10.7150/jca.10638 · Cited by 45
Structural Analysis of the Human Fibroblast Growth Factor Receptor 4 Kinase
Lesca, E., Lammens, A., Huber, R., & Augustin, M. A. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.09.004 · Cited by 43
Luo, L. Y., Kim, E., Cheung, H. W., Weir, B. A., Dunn, G. P., Shen, R. R., & Hahn, W. C. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0407 · Cited by 43
Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer
Fischbach, A., Rogler, A., Erber, R., Stoehr, R., Poulsom, R., Heidenreich, A., Schneevoigt, B., Hauke, S., Hartmann, A., Knuechel, R., et al. (2015) · Histopathology · doi:10.1111/his.12473 · Cited by 42
Sieglitz, F., Matzat, T., Yuva-Aydemir, Y., Neuert, H., Altenhein, B., & Klämbt, C. (2013) · Science Signaling · doi:10.1126/scisignal.2004651 · Cited by 41
mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma
Scheller, T., Hellerbrand, C., Moser, C., Schmidt, K. M., Kroemer, A., Brunner, S., Schlitt, H. J., Geissler, E. K., & Lang, S. A. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.638 · Cited by 40
Kim, B., Wang, S., Lee, J. M., Jeong, Y., Ahn, T., Son, D.-S., Park, H. W., Yoo, H.-S., Song, Y.-J., Lee, E., et al. (2014) · Oncogene · doi:10.1038/onc.2014.51 · Cited by 39
Kotani, H., Ebi, H., Kitai, H., Nanjo, S., Kita, K., Huynh, T. G., Ooi, A., Faber, A. C., Mino-Kenudson, M. A., & Yano, S. (2015) · Oncogene · doi:10.1038/onc.2015.426 · Cited by 38
Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2
Tanizaki, J., Ercan, D., Capelletti, M., Dodge, M. E., Xu, C., Bahcall, M., Tricker, E. M., Butaney, M., Calles, A., Sholl, L. M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3771 · Cited by 35
Timsah, Z., Ahmed, Z., Ivan, C., Berrout, J., Gagea, M., Zhou, Y., Armaiz-Peña, G. N., Hu, X., Vallien, C., Kingsley, C. V., et al. (2015) · Oncogene · doi:10.1038/onc.2015.279 · Cited by 31
Verstraete, M., Debucquoy, A., Gonnissen, A., Dok, R., Isebaert, S. F., Devos, E., McBride, W. H., & Haustermans, K. M. (2015) · BMC Cancer · doi:10.1186/s12885-015-2000-8 · Cited by 30
Giacomini, A., Matarazzo, S., Pagano, K., Ragona, L., Rezzola, S., Corsini, M., Salle, E. D., Presta, M., & Ronca, R. (2015) · Oncotarget · doi:10.18632/oncotarget.3831 · Cited by 28
Lee, E. K., Martínez, M. C. R., Blakely, K. M., Santos, K. D., Hoang, V. C., Chow, A., & Emmenegger, U. (2014) · Medical Hypotheses · doi:10.1016/j.mehy.2014.08.005 · Cited by 23
Tuomela, J. M., & Härkönen, P. L. (2014) · Reproductive Biology · doi:10.1016/j.repbio.2014.01.002 · Cited by 18
Andersen, S. W., Trentham‐Dietz, A., Figueroa, J. D., Titus, L. J., Cai, Q., Long, J., Hampton, J. M., Egan, K. M., & Newcomb, P. A. (2012) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e318268ca46 · Cited by 14
Grb-ing receptor activation by the tail
Fearon, A. E., & Grose, R. P. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2767 · Cited by 8
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Molecular therapies and precision medicine for hepatocellular carcinoma
Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,938
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Abou-Alfa, G. K., Sahai, V., Hollebecque, A., Vaccaro, G., Melisi, D., Al-Rajabi, R., Paulson, A. S., Borad, M. J., Gallinson, D., Murphy, A. G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30109-1 · Cited by 1,611
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Metadata
- Authors
- Babina, I. S., & Turner, N. C.
- Venue
- Nature Reviews Cancer
- Published
- 2017-03-17
- Volume
- 17
- Issue
- 5
- Pages
- 318-332
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2595713273
- Cited by
- 799
- References
- 157
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.